{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:38:16Z","timestamp":1792827496217,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006108","name":"national center for advancing translational sciences","doi-asserted-by":"publisher","award":["UL1TR000142"],"award-info":[{"award-number":["UL1TR000142"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"national center for advancing translational sciences","doi-asserted-by":"publisher","award":["KL2-TR001862"],"award-info":[{"award-number":["KL2-TR001862"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12016-021-08906-w","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T06:02:43Z","timestamp":1634968963000},"page":"264-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-3196","authenticated-orcid":false,"given":"Katelyn H.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"8906_CR1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser GP, Dattwyler RJ, Shapiro ED et al (2006) The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089\u20131134. https:\/\/doi.org\/10.1086\/508667","journal-title":"Clin Infect Dis"},{"key":"8906_CR2","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ije\/dyi241","volume":"34","author":"ED Shapiro","year":"2005","unstructured":"Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP (2005) Response to meta-analysis of Lyme borreliosis symptoms. Int Epidemiol Assoc Int J Epidemiol 34:1437\u20131439. https:\/\/doi.org\/10.1093\/ije\/dyi241","journal-title":"Int Epidemiol Assoc Int J Epidemiol"},{"key":"8906_CR3","doi-asserted-by":"publisher","unstructured":"Shapiro ED (2014) Clinical practice: Lyme disease. N Engl J Med 371.\u00a0https:\/\/doi.org\/10.1056\/NEJMc1407264","DOI":"10.1056\/NEJMc1407264"},{"key":"8906_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJMra072023","volume":"357","author":"HM Feder","year":"2007","unstructured":"Feder HM, Johnson BJB, O\u2019Connell S et al (2007) A critical appraisal of chronic lyme disease. N Engl J Med 357:1422","journal-title":"N. Engl. J. Med."},{"key":"8906_CR5","doi-asserted-by":"publisher","unstructured":"Dahlhamer J, Lucas J, Zelaya C et al (2018) Prevalence of chronic pain and high-impact chronic pain among adults\u2014United States, 2016. MMWR Morb Mortal Wkly Rep 67:1001\u20131006. https:\/\/doi.org\/10.15585\/mmwr.mm6736a2","DOI":"10.15585\/mmwr.mm6736a2"},{"key":"8906_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.jom.0000249782.60321.2a","volume":"49","author":"JA Ricci","year":"2007","unstructured":"Ricci JA, Chee E, Lorandeau AL, Berger J (2007) Fatigue in the U.S. workforce: prevalence and implications for lost productive work time. J Occup Environ Med 49:1\u201310. https:\/\/doi.org\/10.1097\/01.jom.0000249782.60321.2a","journal-title":"J Occup Environ Med"},{"key":"8906_CR7","first-page":"275","volume":"62","author":"D Blackwell","year":"2013","unstructured":"Blackwell D, Clarke TC (2013) QuickStats: percentage of adults who often felt very tired or exhausted in the past 3 months,* by sex and age group\u2014national health interview survey, United States, 2010\u20132011\u2020. MMWR Morb Mortal Wkly Rep 62:275","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"8906_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/00006454-199609000-00003","volume":"15","author":"EG Seltzer","year":"1996","unstructured":"Seltzer EG, Shapiro ED (1996) Misdiagnosis of Lyme disease: When not to order serologic tests. Pediatr Infect Dis J 15:762\u2013763","journal-title":"Pediatr. Infect. Dis. J."},{"key":"8906_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.7326\/0003-4819-127-12-199712150-00011","volume":"127","author":"P Tugwell","year":"1997","unstructured":"Tugwell P, Dennis DT, Weinstein A et al (1997) Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 127:1109\u20131123. https:\/\/doi.org\/10.7326\/0003-4819-127-12-199712150-00011","journal-title":"Ann Intern Med"},{"key":"8906_CR10","doi-asserted-by":"publisher","unstructured":"Lipsett SC, Branda JA, Nigrovic LE (2019) Evaluation of the modified two-tiered testing method for diagnosis of Lyme disease in children. J Clin Microbiol 57.\u00a0https:\/\/doi.org\/10.1128\/JCM.00547-19","DOI":"10.1128\/JCM.00547-19"},{"key":"8906_CR11","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/cid\/cix043","volume":"64","author":"JA Branda","year":"2017","unstructured":"Branda JA, Strle K, Nigrovic LE et al (2017) Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. Clin Infect Dis 64:1074\u20131080. https:\/\/doi.org\/10.1093\/cid\/cix043","journal-title":"Clin Infect Dis"},{"key":"8906_CR12","doi-asserted-by":"publisher","unstructured":"Pegalajar-Jurado A, Schriefer ME, Welch RJ et al (2018) Evaluation of modified two-tiered testing algorithms for lyme disease laboratory diagnosis using well-characterized serum samples. J Clin Microbiol 56.\u00a0https:\/\/doi.org\/10.1128\/JCM.01943-17","DOI":"10.1128\/JCM.01943-17"},{"key":"8906_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10067-014-2706-z","volume":"34","author":"AW Rebman","year":"2014","unstructured":"Rebman AW, Crowder LA, Kirkpatrick A, Aucott JN (2014) Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients. Clin Rheumatol 34:585\u2013589. https:\/\/doi.org\/10.1007\/s10067-014-2706-z","journal-title":"Clin Rheumatol"},{"key":"8906_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3201\/eid2207.151694","volume":"22","author":"A Moore","year":"2016","unstructured":"Moore A, Nelson C, Molins C et al (2016) Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of lyme disease, United States. Emerg Infect Dis 22:1169\u20131177. https:\/\/doi.org\/10.3201\/eid2207.151694","journal-title":"Emerg Infect Dis"},{"key":"8906_CR15","unstructured":"Centers for Disease Control and Prevention (2013) Lyme disease diagnosis and testing. In: Centers Dis. Control Prev. http:\/\/www.cdc.gov\/lyme\/diagnosistesting\/index.html. Accessed 15 May 2020"},{"key":"8906_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1086\/322669","volume":"33","author":"RA Kalish","year":"2001","unstructured":"Kalish RA, McHugh G, Granquist J et al (2001) Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10\u201320 years after active Lyme disease. Clin Infect Dis 33:780\u2013785. https:\/\/doi.org\/10.1086\/322669","journal-title":"Clin Infect Dis"},{"key":"8906_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00006454-200201000-00003","volume":"21","author":"M Qureshi","year":"2002","unstructured":"Qureshi M, New D, Zulqarni N, Nachman S (2002) Overdiagnosis and overtreatment of Lyme disease in children. Pediatr Infect Dis J 21:12\u201314. https:\/\/doi.org\/10.1097\/00006454-200201000-00003","journal-title":"Pediatr Infect Dis J"},{"key":"8906_CR18","doi-asserted-by":"publisher","unstructured":"Kobayashi T, Higgins Y, Samuels R et al (2019) Misdiagnosis of Lyme disease with unnecessary antimicrobial treatment characterizes patients referred to an academic infectious diseases. Clinic Open forum Infect Dis 6.\u00a0https:\/\/doi.org\/10.1093\/OFID\/OFZ299","DOI":"10.1093\/OFID\/OFZ299"},{"key":"8906_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.7326\/0003-4819-128-5-199803010-00003","volume":"128","author":"M Reid","year":"1998","unstructured":"Reid M, Schoen R, Evans J et al (1998) The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 128:354\u2013362. https:\/\/doi.org\/10.7326\/0003-4819-128-5-199803010-00003","journal-title":"Ann Intern Med"},{"key":"8906_CR20","doi-asserted-by":"publisher","unstructured":"Fallon BA, Pavlicova M, Coffino SW, Brenner C (2014) A comparison of Lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment. https:\/\/doi.org\/10.1093\/cid\/ciu703","DOI":"10.1093\/cid\/ciu703"},{"key":"8906_CR21","unstructured":"Centers for Disease Control and Prevention (2018) Laboratory tests that are not recommended. In: Centers Dis. Control Prev. https:\/\/www.cdc.gov\/lyme\/diagnosistesting\/labtest\/otherlab\/index.html. Accessed 5 Jul 2020"},{"key":"8906_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy614","author":"SE Schutzer","year":"2019","unstructured":"Schutzer SE, Body BA, Boyle J et al (2019) Direct diagnostic tests for Lyme disease. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciy614","journal-title":"Clin Infect Dis"},{"key":"8906_CR23","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1038\/nrdp.2016.90","volume":"2","author":"AC Steere","year":"2016","unstructured":"Steere AC, Strle F, Wormser GP et al (2016) Lyme borreliosis. Nat Rev Dis Prim 2:16090. https:\/\/doi.org\/10.1038\/nrdp.2016.90","journal-title":"Nat Rev Dis Prim"},{"key":"8906_CR24","doi-asserted-by":"publisher","first-page":"13498","DOI":"10.1073\/pnas.1904170116","volume":"116","author":"BL Jutras","year":"2019","unstructured":"Jutras BL, Lochhead RB, Kloos ZA et al (2019) Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis. Proc Natl Acad Sci U S A 116:13498\u201313507. https:\/\/doi.org\/10.1073\/pnas.1904170116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8906_CR25","doi-asserted-by":"publisher","unstructured":"Lantos PM, Lantos PM, Rumbaugh J et al (2020) Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1215","DOI":"10.1093\/cid\/ciaa1215"},{"key":"8906_CR26","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1172\/JCI138062","volume":"130","author":"AC Steere","year":"2020","unstructured":"Steere AC (2020) Posttreatment Lyme disease syndromes: distinct pathogenesis caused by maladaptive host responses. J Clin Invest 130:2148\u20132151. https:\/\/doi.org\/10.1172\/JCI138062","journal-title":"J Clin Invest"},{"key":"8906_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1074\/jbc.REV119.008583","volume":"295","author":"G Chaconas","year":"2020","unstructured":"Chaconas G, Castellanos M, Verhey TB (2020) Changing of the guard: how the Lyme disease spirochete subverts the host immune response. J Biol Chem 295:301\u2013313. https:\/\/doi.org\/10.1074\/jbc.REV119.008583","journal-title":"J Biol Chem"},{"key":"8906_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00116","volume":"8","author":"KE Tracy","year":"2017","unstructured":"Tracy KE, Baumgarth N (2017) Borrelia burgdorferi manipulates innate and adaptive immunity to establish persistence in rodent reservoir hosts. Front Immunol 8:1\u201311. https:\/\/doi.org\/10.3389\/fimmu.2017.00116","journal-title":"Front Immunol"},{"key":"8906_CR29","first-page":"125","volume":"27","author":"J Feng","year":"2019","unstructured":"Feng J, Li T, Yee R et al (2019) Stationary phase persister\/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, post-treatment Lyme disease syndrome (PTLDS), and treatment failure. Discov Med 27:125\u2013138","journal-title":"Discov Med"},{"key":"8906_CR30","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1128\/AAC.00864-15","volume":"59","author":"B Sharma","year":"2015","unstructured":"Sharma B, Brown AV, Matluck NE et al (2015) Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother 59:4616\u20134624. https:\/\/doi.org\/10.1128\/AAC.00864-15","journal-title":"Antimicrob Agents Chemother"},{"key":"8906_CR31","doi-asserted-by":"crossref","unstructured":"Feng J, Shi W, Zhang S, Zhang Y (2015) Persister mechanisms in Borrelia burgdorferi: implications for improved intervention. Emerg. Microbes Infect 4:e51","DOI":"10.1038\/emi.2015.56"},{"key":"8906_CR32","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1128\/AAC.00883-15","volume":"59","author":"JR Caskey","year":"2015","unstructured":"Caskey JR, Embers ME (2015) Persister development by Borrelia burgdorferi populations in vitro. Antimicrob Agents Chemother 59:6288\u20136295. https:\/\/doi.org\/10.1128\/AAC.00883-15","journal-title":"Antimicrob Agents Chemother"},{"key":"8906_CR33","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1111\/1462-2920.13897","volume":"19","author":"FC Cabello","year":"2017","unstructured":"Cabello FC, Godfrey HP, Bugrysheva JV, Newman SA (2017) Sleeper cells: the stringent response and persistence in the Borreliella (Borrelia) burgdorferi enzootic cycle. Environ. Microbiol. 19:3846\u20133862","journal-title":"Environ. Microbiol."},{"key":"8906_CR34","doi-asserted-by":"publisher","unstructured":"Hodzic E, Imai DM, Escobar E (2019) Generality of post-antimicrobial treatment persistence of borrelia burgdorferi strains N40 and B31 in genetically susceptible and resistant mouse strains. Infect Immun 87.\u00a0https:\/\/doi.org\/10.1128\/IAI.00442-19","DOI":"10.1128\/IAI.00442-19"},{"key":"8906_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/000992289703600514","volume":"35","author":"RK Straubinger","year":"1997","unstructured":"Straubinger RK, Summers BA, Chang YF, Appel MJG (1997) Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 35:111\u2013116. https:\/\/doi.org\/10.1177\/000992289703600514","journal-title":"J Clin Microbiol"},{"key":"8906_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0029914","volume":"7","author":"ME Embers","year":"2012","unstructured":"Embers ME, Barthold SW, Borda JT et al (2012) Persistence of borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 7:1\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0029914","journal-title":"PLoS One"},{"key":"8906_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/0002-9343(93)90208-7","volume":"94","author":"RB Nadelman","year":"1993","unstructured":"Nadelman RB, Nowakowski J, Forseter G et al (1993) Failure to isolate borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: Report of a prospective study. Am J Med 94:583\u2013588. https:\/\/doi.org\/10.1016\/0002-9343(93)90208-7","journal-title":"Am J Med"},{"key":"8906_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.04.014","author":"PJ Baker","year":"2017","unstructured":"Baker PJ, Wormser GP (2017) The clinical relevance of studies on borrelia burgdorferi persisters. Am J Med. https:\/\/doi.org\/10.1016\/j.amjmed.2017.04.014","journal-title":"Am J Med"},{"key":"8906_CR39","doi-asserted-by":"crossref","unstructured":"Hunfeld KP, Kraiczy P, Kekoukh E et al (2002) Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents - Possible implications for new therapeutic approaches to lyme disease. In: International Journal of Medical Microbiology. Elsevier GmbH, pp 125\u2013137","DOI":"10.1016\/S1438-4221(02)80024-8"},{"key":"8906_CR40","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1002\/art.25005","volume":"60","author":"BP Iliopoulou","year":"2009","unstructured":"Iliopoulou BP, Guerau-de-Arellano M, Huber BT (2009) HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis. Arthritis Rheum 60:3831\u20133840. https:\/\/doi.org\/10.1002\/art.25005","journal-title":"Arthritis Rheum"},{"key":"8906_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20052471","volume":"203","author":"AC Steere","year":"2006","unstructured":"Steere AC, Klitz W, Drouin EE et al (2006) Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 203:961\u2013971. https:\/\/doi.org\/10.1084\/jem.20052471","journal-title":"J Exp Med"},{"key":"8906_CR42","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1172\/JCI58813","volume":"122","author":"LK Bockenstedt","year":"2012","unstructured":"Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA (2012) Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 122:2652\u20132660. https:\/\/doi.org\/10.1172\/JCI58813","journal-title":"J Clin Invest"},{"key":"8906_CR43","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/cid\/cix002","volume":"64","author":"K Strle","year":"2017","unstructured":"Strle K, Sulka KB, Pianta A et al (2017) T-Helper 17 cell cytokine responses in Lyme disease correlate with borrelia burgdorferi antibodies during early infection and with autoantibodies late in the illness in patients with antibiotic-refractory Lyme arthritis. Clin Infect Dis 64:930\u2013938. https:\/\/doi.org\/10.1093\/cid\/cix002","journal-title":"Clin Infect Dis"},{"key":"8906_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1189\/jlb.2RU0714-343RR","volume":"97","author":"A Divan","year":"2015","unstructured":"Divan A, Budd RC, Tobin RP, Newell-Rogers MK (2015) \u03b3\u03b4 T Cells and dendritic cells in refractory Lyme arthritis. J Leukoc Biol 97:653\u2013663","journal-title":"J. Leukoc. Biol."},{"key":"8906_CR45","doi-asserted-by":"publisher","unstructured":"Lochhead RB, Arvikar SL, Aversa JM et al (2019) Robust interferon signature and suppressed tissue repair gene expression in synovial tissue from patients with postinfectious Borrelia burgdorferi-induced Lyme arthritis. Cell Microbiol 21.\u00a0https:\/\/doi.org\/10.1111\/cmi.12954","DOI":"10.1111\/cmi.12954"},{"key":"8906_CR46","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/art.37910","volume":"65","author":"NK Vudattu","year":"2013","unstructured":"Vudattu NK, Strle K, Steere AC, Drouin EE (2013) Dysregulation of CD4+CD25high T cells in the synovial fluid of patients with antibiotic-refractory lyme arthritis. Arthritis Rheum 65:1643\u20131653. https:\/\/doi.org\/10.1002\/art.37910","journal-title":"Arthritis Rheum"},{"key":"8906_CR47","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/art.22441","volume":"56","author":"JJ Shin","year":"2007","unstructured":"Shin JJ, Glickstein LJ, Steere AC (2007) High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum 56:1325\u201335. https:\/\/doi.org\/10.1002\/art.22441","journal-title":"Arthritis Rheum"},{"key":"8906_CR48","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3899\/jrheum.090711","volume":"37","author":"HO Tory","year":"2010","unstructured":"Tory HO, Zurakowski D, Sundel RP (2010) Outcomes of children treated for lyme arthritis: Results of a large pediatric cohort. J Rheumatol 37:1049\u20131055. https:\/\/doi.org\/10.3899\/jrheum.090711","journal-title":"J Rheumatol"},{"key":"8906_CR49","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1002\/art.22131","volume":"54","author":"AC Steere","year":"2006","unstructured":"Steere AC, Angelis SM (2006) Therapy for lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54:3079\u20133086","journal-title":"Arthritis Rheum."},{"key":"8906_CR50","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1128\/CVI.00071-16","volume":"23","author":"JN Aucott","year":"2016","unstructured":"Aucott JN, Soloski MJ, Rebman AW et al (2016) CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol 23:757\u2013766. https:\/\/doi.org\/10.1128\/CVI.00071-16","journal-title":"Clin Vaccine Immunol"},{"key":"8906_CR51","doi-asserted-by":"publisher","unstructured":"Strle K, Stupica D, Drouin EE et al (2013) Elevated levels of IL-23 in a subset of patients with post-Lyme disease symptoms following erythema migrans. https:\/\/doi.org\/10.1093\/cid\/cit735","DOI":"10.1093\/cid\/cit735"},{"key":"8906_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw599","author":"M Uhde","year":"2016","unstructured":"Uhde M, Ajamian M, Li X et al (2016) Expression of C-reactive protein and serum amyloid A in early to late manifestations of Lyme disease. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciw599","journal-title":"Clin Infect Dis"},{"key":"8906_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jneuroim.2012.10.011","volume":"255","author":"E Jacek","year":"2013","unstructured":"Jacek E, Fallon BA, Chandra A et al (2013) Increased IFN\u03b1 activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits. J Neuroimmunol 255:85\u201391","journal-title":"J. Neuroimmunol."},{"key":"8906_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM200107123450202","volume":"345","author":"MS Klempner","year":"2001","unstructured":"Klempner MS, Hu LT, Evans J et al (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345:85\u201392. https:\/\/doi.org\/10.1056\/NEJM200107123450202","journal-title":"N Engl J Med"},{"key":"8906_CR55","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bmj.38933.585764.AE","volume":"333","author":"I Hickie","year":"2006","unstructured":"Hickie I, Davenport T, Wakefield D et al (2006) Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. Br Med J 333:575\u2013578. https:\/\/doi.org\/10.1136\/bmj.38933.585764.AE","journal-title":"Br Med J"},{"key":"8906_CR56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1176\/appi.neuropsych.12090223","volume":"25","author":"S Batheja","year":"2013","unstructured":"Batheja S, Nields JA, Landa A, Fallon BA (2013) Post-treatment lyme syndrome and central sensitization. J Neuropsychiatry Clin Neurosci 25:176\u2013186","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"8906_CR57","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ART.38972","volume":"67","author":"GP Wormser","year":"2015","unstructured":"Wormser GP, Weitzner E, McKenna D et al (2015) Brief report: long-term assessment of fibromyalgia in patients with culture-confirmed Lyme disease. Arthritis Rheumatol 67:837\u2013839. https:\/\/doi.org\/10.1002\/ART.38972","journal-title":"Arthritis Rheumatol"},{"key":"8906_CR58","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/JAMA.283.5.609","volume":"283","author":"S Eg","year":"2000","unstructured":"Eg S, Ma G, Ml C et al (2000) Long-term outcomes of persons with Lyme disease. JAMA 283:609\u2013616. https:\/\/doi.org\/10.1001\/JAMA.283.5.609","journal-title":"JAMA"},{"key":"8906_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.idc.2015.02.006","volume":"29","author":"PM Lantos","year":"2015","unstructured":"Lantos PM (2015) Chronic Lyme disease. Infect Dis Clin North Am 29:325\u2013340","journal-title":"Infect. Dis. Clin. North Am."},{"key":"8906_CR60","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1212\/01.WNL.0000071227.23769.9E","volume":"60","author":"LB Krupp","year":"2003","unstructured":"Krupp LB, Hyman LG, Grimson R et al (2003) Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60:1923\u20131930. https:\/\/doi.org\/10.1212\/01.WNL.0000071227.23769.9E","journal-title":"Neurology"},{"key":"8906_CR61","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/01.WNL.0000068030.26992.25","volume":"60","author":"RF Kaplan","year":"2003","unstructured":"Kaplan RF, Trevino RP, Johnson GM et al (2003) Cognitive function in post-treatment Lyme disease: Do additional antibiotics help? Neurology 60:1916\u20131922. https:\/\/doi.org\/10.1212\/01.WNL.0000068030.26992.25","journal-title":"Neurology"},{"key":"8906_CR62","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1212\/01.wnl.0000284604.61160.2d","volume":"70","author":"BA Fallon","year":"2008","unstructured":"Fallon BA, Keilp JG, Corbera KM et al (2008) A randomized, placebo-controlled trial of repeated iv antibiotic therapy for lyme encephalopathy symbol. Neurology 70:992\u20131003. https:\/\/doi.org\/10.1212\/01.wnl.0000284604.61160.2d","journal-title":"Neurology"},{"key":"8906_CR63","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1086\/318138","volume":"31","author":"R Patel","year":"2000","unstructured":"Patel R, Grogg KL, Edwards WD et al (2000) Death from inappropriate therapy for Lyme disease. Clin Infect Dis 31:1107\u20131109. https:\/\/doi.org\/10.1086\/318138","journal-title":"Clin Infect Dis"},{"key":"8906_CR64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/01.wnl.0000265517.66976.28","volume":"69","author":"JJ Halperin","year":"2007","unstructured":"Halperin JJ, Shapiro ED, Logigian E et al (2007) Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 69:91\u2013102. https:\/\/doi.org\/10.1212\/01.wnl.0000265517.66976.28","journal-title":"Neurology"},{"key":"8906_CR65","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa1505425","volume":"374","author":"A Berende","year":"2016","unstructured":"Berende A, Hofstede HJMT, Vos FJ et al (2016) Randomized trial of longer-term therapy for symptoms attributed to lyme disease. N Engl J Med 374:1209\u20131220. https:\/\/doi.org\/10.1056\/NEJMoa1505425","journal-title":"N Engl J Med"},{"key":"8906_CR66","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/cid\/ciy329","volume":"67","author":"KJ Goodlet","year":"2018","unstructured":"Goodlet KJ, Fairman KA (2018) Adverse events associated with antibiotics and intravenous therapies for post-lyme disease syndrome in a commercially insured sample. Clin Infect Dis 67:1568\u20131574. https:\/\/doi.org\/10.1093\/cid\/ciy329","journal-title":"Clin Infect Dis"},{"key":"8906_CR67","doi-asserted-by":"publisher","unstructured":"Marzec NS, Nelson C, Waldron PR et al (2017) Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease\u2014United States. MMWR Morb Mortal Wkly Rep 66:607\u2013609. https:\/\/doi.org\/10.15585\/mmwr.mm6623a3","DOI":"10.15585\/mmwr.mm6623a3"},{"key":"8906_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ186","author":"PM Lantos","year":"2015","unstructured":"Lantos PM, Shapiro ED, Auwaerter PG et al (2015) Unorthodox alternative therapies marketed to treat Lyme disease. https:\/\/doi.org\/10.1093\/cid\/civ186","journal-title":"Unorthodox alternative therapies marketed to treat Lyme disease."},{"key":"8906_CR69","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1212\/WNL.46.4.1174","volume":"46","author":"D Crisp","year":"1996","unstructured":"Crisp D, Ashby P (1996) Lyme radiculoneuritis treated with intravenous immunoglobulin. Neurology 46:1174\u20131175. https:\/\/doi.org\/10.1212\/WNL.46.4.1174","journal-title":"Neurology"},{"key":"8906_CR70","unstructured":"Celik T, Celik U, K\u00f6m\u00fcr M et al (2016) Pediatric Lyme neuroborreliosis: different clinical presentations of the same agent; single center experience. Neuro Endocrinol Lett 37"},{"key":"8906_CR71","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1097\/PEC.0b013e318276c51d","volume":"28","author":"R Rocha","year":"2012","unstructured":"Rocha R, Lisboa L, Neves J et al (2012) Neuroborreliosis presenting as acute disseminated encephalomyelitis. Pediatr Emerg Care 28:1374\u20131376. https:\/\/doi.org\/10.1097\/PEC.0b013e318276c51d","journal-title":"Pediatr Emerg Care"},{"key":"8906_CR72","unstructured":"Gannon M (2005) Alternative treatment gives patient a chance at a pain-free life. New Haven Regist. https:\/\/www.nhregister.com\/news\/article\/Alternative-treatment-gives-patient-a-chance-at-a-11651283.php. Accessed 12 Jul 2020"},{"key":"8906_CR73","unstructured":"Fallon B, Marconi R (2009) 2009 10th Annual Scientific Conference: 34 Years, From Lyme, CT, Across the Nation Conference Summary. Lyme Dis Assoc. https:\/\/lymediseaseassociation.org\/lda-conferences\/summary-pages\/2009-conf-summary\/. Accessed 12 Jul 2020"},{"key":"8906_CR74","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","volume":"27","author":"ER Stiehm","year":"2013","unstructured":"Stiehm ER (2013) Adverse effects of human immunoglobulin therapy. Transfus Med Rev 27:171\u2013178. https:\/\/doi.org\/10.1016\/j.tmrv.2013.05.004","journal-title":"Transfus Med Rev"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08906-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08906-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08906-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T13:18:48Z","timestamp":1644067128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08906-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["8906"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08906-w","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,23]]},"assertion":[{"value":"27 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Shapiro has served as an expert witness, has received an honorarium for consulting with Pfizer, and receives royalties from UptoDate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}